In full bloom: WEECO Pharma boosts SYNBIOTIC's sales

The acquisition of WEECO Pharma by the European hemp and cannabis group SYNBIOTIC SE (ISIN DE000A3E5A59 | WKN A3E5A5) is proving to be a valuable deal in the truest sense of the word. WEECO Pharma is well above the previously planned revenue target for 2024, at EUR 6.75 million as of the end of October 2024. Revenues of over EUR 8 million are expected for the full year 2024. For this reason, WEECO Pharma's sales plans for 2025 and 2026 will be realistically, but still conservatively, adjusted upwards in the coming weeks.

“We firmly believed that our partnership would create positive synergies for both sides. Despite our great confidence, we would never have dreamt that we would be able to present such figures so soon. The whole is indeed more than the sum of its parts,” explain Börge Diessel, Managing Director of WEECO Pharma, and Daniel Kruse, CEO of SYNBIOTIC.

As a German importer and wholesaler, WEECO Pharma brings together an international network of medical cannabis producers, including some of the world's leading EU GMP manufacturers. The company specialises in the national and international trade in medicinal cannabis, including proprietary genetics. With WEECO Pharma, SYNBIOTIC has a full range of high-quality cannabis flowers within the group of companies. WEECO Pharma benefits from proven structures, experienced managers and contacts with suppliers from other SYNBIOTIC subsidiaries, specifically MH medical hemp and SynBiotic Distribution. This enables the group to fully exploit its potential. At the same time, SYNBIOTIC is planning further acquisitions in the areas of cultivation and the supply chain for medical cannabis.

“WEECO has developed into a real asset for our investors and shareholders in a very short space of time,” confirms Daniel Kruse. “Over the next 18 months, we will increasingly focus on the extremely growing market for medical cannabis.”

And this is also fuelling current discussions with potential investors. SYNBIOTIC's Investor Relations team is using the good news for an extended November roadshow.

SYNBIOTIC On the Road Again

mwb research from Hamburg, one of the largest analysis firms in Europe, organised an exclusive online presentation for investors at the launch. Daniel Kruse presented SYNBIOTIC's strategy together with Lukas Kendel and Emilio Ropero from SYNBIOTIC's management team and answered questions from selected investors.

As part of the Talman event "Shape the Future of Cannabis Investment" in Munich, Daniel Kruse discussed investment opportunities in the emerging legal cannabis industry as a panellist with other experts from the cannabis industry. The Talman House is a members-only service that connects investors with successful cannabis companies in Europe and around the world. SYNBIOTIC also supported the event on the second weekend of November as a Gold Sponsor.

From 25 to 27 November, SYNBIOTIC's IR team, headed by Daniel Kruse, will be a guest at the German Equity Forum. The event, organised by Deutsche Börse AG, is one of the most important capital market events about corporate financing in Europe. At the Steigenberger Airport Hotel Frankfurt, institutional investors and financial analysts enter dialogue with around 250 listed companies. In addition to SYNBIOTIC, there are also several DAX-listed companies on the list of registered companies.

Diversity advantage

As a European industrial hemp and cannabis group, SYNBIOTIC has a decisive unique selling point: no market competitor offers investors a comparably high degree of diversification in the industrial hemp and cannabis sector. Through its investments, SYNBIOTIC covers the entire value chain of the industrial hemp and cannabis sector. The successful continuation of the buy and build strategy will further extend this advantage.

Publisher
SYNBIOTIC SE
Daniel Kruse
CEO
Münsterstraße 336
40470 Düsseldorf
Germany

Media contact
Rüdiger Tillmann
SYNBIOTIC
Public Relations Manager
E-mail ruediger.tillmann@synbiotic.com
Mobile +49 170 9651451
c/o JOLE.group

About SYNBIOTIC
SYNBIOTIC is a listed group of companies in the hemp and cannabis sector and pursues a buy and build investment strategy focussed on the EU. 
The Group covers the entire value chain from cultivation to production and retail - from the field to the shelf. The core businesses of the vertically integrated subsidiaries are research and development, production and the commercialisation of hemp, CBD and cannabis products.
SYNBIOTIC has a clear pan-European strategy to further expand along the value chains of its business areas - hemp and CBD, medical cannabis and consumer cannabis.